Rabeprazole sodium

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

GERD

Conditions

GERD

Trial Timeline

Mar 1, 2008 → Sep 1, 2009

NCT ID

NCT00747695

About Rabeprazole sodium

Rabeprazole sodium is a phase 1 stage product being developed by Eisai for GERD. The current trial status is completed. This product is registered under clinical trial identifier NCT00747695. Target conditions include GERD.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01264822	Pre-clinical	Completed	Jan 13, 2011	Nov 17, 2016	Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
NCT01321567	Pre-clinical	Completed	Jan 1, 2011	Aug 1, 2013	Refractory Reflux Esophagitis
NCT00855361	Phase 1	Completed	Jul 1, 2009	Dec 1, 2011	Gastroesophageal Reflux
NCT00747695	Phase 1	Completed	Mar 1, 2008	Sep 1, 2009	GERD
NCT01286194	Pre-clinical	Completed	Apr 1, 2006	Jan 1, 2007	Frequent Heartburn
NCT00236184	Phase 3	Completed	Oct 1, 2005	Jun 1, 2008	Heartburn
NCT00132496	Phase 2	Completed	Aug 1, 2005	Jul 1, 2006	Gastroesophageal Reflux Disease

Competing Products

20 competing products in GERD

See all competitors

Product	Company	Stage	Hype Score
Rabeprazole ER + Ranitidine	Eisai	Phase 3	77
Rabeprazole sodium + Esomeprazole	Eisai	Phase 3	77
rabeprazole sodium + Placebo	Eisai	Phase 3	77
Rabeprazole ER + Ranitidine	Eisai	Phase 3	77
Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg	Eisai	Phase 1	33
rabeprazole + rabeprazole	Eisai	Phase 3	77
Rabeprazole sodium + Esomeprazole	Eisai	Phase 3	77
Rabeprazole sodium + Esomeprazole	Eisai	Phase 3	77
ONO-8539	Ono Pharmaceutical	Phase 1	33
esomeprazole 40 mg	Johnson & Johnson	Pre-clinical	23
esomeprazole (Nexium®) + Xolaam®	AstraZeneca	Approved	85
esomeprazole	AstraZeneca	Pre-clinical	23
Esomeprazole	AstraZeneca	Approved	85
Esomeprazole	AstraZeneca	Approved	85
esomeprazole magnesium	AstraZeneca	Phase 1	33
Esomeprazole	AstraZeneca	Approved	85
Esomeprazole	AstraZeneca	Phase 3	77
Esomeprazole (Nexium)	AstraZeneca	Approved	85
Omeprazole	AstraZeneca	Phase 3	77
Open Label Run In Esomeprazole + Double Blind Esomeprazole + Double Blind Placebo	AstraZeneca	Phase 3	77

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved